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ABSTRACT  
For clinical grade human embryonic stem cell (hESC) lines, a robust derivation and culture 
system without any substances having animal origin would be optimal. The general aims of these 
studies have been to gradually improve our hESC derivation and cultures.  
The first step towards clinical quality was the use of human foreskin fibroblasts instead of mouse 
embryonic fibroblasts to support the undifferentiated growth of the pluripotent stem cells. This 
was followed by replacing foetal calf serum as a supplement in the culture medium with the 
commercially available Serum Replacement, first in the cultures and later also for the derivation 
of new hESC lines.  
The immunosurgery generally used for isolation of the inner cell mass (ICM) involves animal 
serum and complement. We have been able to replace the surgical method with a mechanical 
procedure for the isolation of the inner cell mass, and this gives better results.  
We have also evaluated whether the morphology of the embryos donated to stem cell research has 
an impact on derivation success. We have carried out statistical analyses on the early cleavage 
rate, morphological score of the embryo at cleavage stage and the score for the ICM and the 
trophectoderm at the time for isolation of the ICM. We have shown that there is no correlation 
between the morphology and derivation success. All embryos donated for stem cell research 
should be used for isolation in an attempt to derive new hESC lines. Even embryos with no visible 
ICM have generated pluripotent hESCs.  
In the final study we have been able to culture hESCs on a human recombinant laminin, LN-511, 
for more than 20 passages (four months) in a well-defined medium devoid of any animal-derived 
components. The use of a well-defined system is most important in understanding the pluripotent 
state and being able to direct the differentiation in the desired direction for clinical applications in 
the future.  
We have taken hESC research from a culture system that depended on several animal-derived 
components to a totally xeno-free system. We hope that these improved culture procedures can be 
used for the development of cell lineages for use in therapeutic purposes.  
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